4.4 Article

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Oncology

Chemotherapy for Triple-Negative Breast Cancer: Is More Better?

Erica L. Mayer et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Review Oncology

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Giampaolo Bianchini et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Article Biochemistry & Molecular Biology

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

X. Lu et al.

ONCOGENE (2013)

Article Biochemistry & Molecular Biology

Suppression of EGFR Autophosphorylation by FKBP12

Sebastian Mathea et al.

BIOCHEMISTRY (2011)

Article Biochemistry & Molecular Biology

MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia

Sheng Zhou et al.

MOLECULAR AND CELLULAR BIOLOGY (2011)

Review Medicine, General & Internal

Triple-Negative Breast Cancer

William D. Foulkes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Review Oncology

p53-independent activities of MDM2 and their relevance to cancer therapy

Z Zhang et al.

CURRENT CANCER DRUG TARGETS (2005)